Neuroendocrine Cancer Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting neuroendocrine cancer clinical trials across 2 countries. Studies span Phase 1, Phase 2, Not Applicable. Top locations include Los Angeles, California, United States, San Antonio, Texas, United States, Fairfax, Virginia, United States. Updated daily from ClinicalTrials.gov.


Neuroendocrine Cancer Trials at a Glance

7 actively recruiting trials for neuroendocrine cancer are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Los Angeles, San Antonio, and Fairfax. Lead sponsors running neuroendocrine cancer studies include Fudan University, National Cancer Institute (NCI), and Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc..

Browse neuroendocrine cancer trials by phase

Treatments under study

About Neuroendocrine Cancer Clinical Trials

Looking for clinical trials for Neuroendocrine Cancer? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuroendocrine Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuroendocrine Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Locally Advanced Merkel Cell CarcinomaSmall Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine Cancer+8 more
SystImmune Inc.120 enrolled20 locationsNCT07080242
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Not Applicable

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

PET/CTNeuroendocrine CancerDLL3-expressing Tumors
The First Affiliated Hospital of Xiamen University60 enrolled1 locationNCT07458906
Recruiting
Phase 1Phase 2

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Small Cell Lung CancerNeuroendocrine Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd265 enrolled1 locationNCT06283719
Recruiting
Phase 1Phase 2

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Small Cell Lung Cancer ( SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Neuroendocrine Carcinomas (NEC)+3 more
Phanes Therapeutics203 enrolled12 locationsNCT05652686
Recruiting
Phase 2

Ivonescimab in the Treatment of Multiple Advanced Tumors

Urothelial CarcinomaSarcomaKidney Cancer+16 more
Fudan University400 enrolled1 locationNCT06683846